Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer, wherein the cancer is an ARID1A-mutated cancer. In some embodiments, the therapeutic treatments disclosed include methods of treating ARID1A-mutated cancer in a subject comprising the step of administering a therapeutically effective dose of a histone deacetylase 6 (HDAC6) inhibitor to the subject, including a human subject. In some embodiments, the HDAC6 inhibitors are administered in conjunction with a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor.

Abstract: Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided.

Abstract: Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided.